ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB) from its SEC filings: 2025 revenue $234.6 million (+157% vs the year before), net margin -6%, free cash flow $19.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $234.6 million |
| Revenue growth | +157% |
| Net income | -$13.2 million |
| Net margin | -5.6% |
| Free cash flow | $19.6 million |
| Diluted EPS | $-0.44 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | -8% |
| Cash | $133.8 million |
| Share count, 1 year | +8% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.